effect of Menaquinone(MK-7) supplementation on deppression status in patients with polycystic ovary syndrome

Not Applicable

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20170916036204N5
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 84

Inclusion Criteria

Suffering from polycystic ovary syndrome based on Rotterdam criteria;
Age between 18 to 40

Exclusion Criteria

Unwillingness to participate
Any disease or physiological changes that requires special treatment
Pregnancy or lactation
Using antidiabetic, antihypertensives, antihyperlipidemics or anticoagulant treatment
Using metformin 2 months before entering the study and during the intervention;
Acute or chronic inflammation
Being smoker or/and alcoholic.
Using drugs effective on bone metabolism
Any current diet or supplement treatment
Using oral contraceptives

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression score in BECK questionnaire. Timepoint: Before and after the intervention. Method of measurement: BECK depression questionnaire.

Secondary Outcome Measures

Name	Time	Method
Serum vitamin K level. Timepoint: Before and after the intervention. Method of measurement: ELISA kit.;Fasting Blood Sugar. Timepoint: Before and after intervention. Method of measurement: auto analyser.